JP2019513412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513412A5 JP2019513412A5 JP2018568171A JP2018568171A JP2019513412A5 JP 2019513412 A5 JP2019513412 A5 JP 2019513412A5 JP 2018568171 A JP2018568171 A JP 2018568171A JP 2018568171 A JP2018568171 A JP 2018568171A JP 2019513412 A5 JP2019513412 A5 JP 2019513412A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- nanoparticles
- paramagnetic
- expanded
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309234P | 2016-03-16 | 2016-03-16 | |
| US62/309,234 | 2016-03-16 | ||
| PCT/US2017/022663 WO2017161092A1 (en) | 2016-03-16 | 2017-03-16 | Production of antigen-specific t-cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513412A JP2019513412A (ja) | 2019-05-30 |
| JP2019513412A5 true JP2019513412A5 (https=) | 2020-04-23 |
| JP7016098B2 JP7016098B2 (ja) | 2022-02-21 |
Family
ID=59850933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568171A Active JP7016098B2 (ja) | 2016-03-16 | 2017-03-16 | 抗原特異的ｔ細胞の生成 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200291381A1 (https=) |
| EP (1) | EP3445399A4 (https=) |
| JP (1) | JP7016098B2 (https=) |
| KR (1) | KR102470979B1 (https=) |
| CN (1) | CN109475620A (https=) |
| AU (1) | AU2017233035B2 (https=) |
| CA (1) | CA3017615A1 (https=) |
| IL (1) | IL261710A (https=) |
| RU (2) | RU2021107053A (https=) |
| SG (2) | SG10202008210XA (https=) |
| WO (1) | WO2017161092A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3475706B1 (en) * | 2016-06-27 | 2021-08-11 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
| BR112020005552A2 (pt) * | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| EP3691662A4 (en) * | 2017-10-06 | 2021-05-12 | The University of Chicago | SCREENING OF T LYMPHOCYTE FOR CANCER SPECIFIC ANTIGENS |
| JP7580754B2 (ja) * | 2018-06-20 | 2024-11-12 | ダンマークス テクニスク ユニバーシテット | 免疫細胞操作用の安定化されたｍｈｃ分子を有するスカフォールド |
| WO2020061256A1 (en) * | 2018-09-19 | 2020-03-26 | FUJIFILM Cellular Dynamics, Inc. | Protein l for activation and expansion of chimeric antigen receptor-modified immune cells |
| CN109136276A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种rfft2细胞的构建方法 |
| SG11202104611YA (en) | 2018-11-08 | 2021-06-29 | Neximmune Inc | T cell compositions with improved phenotypic properties |
| US12600755B2 (en) | 2020-02-27 | 2026-04-14 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Cobra 1/NELF-B as a booster for efficacy of CD8+ T cell-based therapy |
| WO2021262846A1 (en) * | 2020-06-26 | 2021-12-30 | The Johns Hopkins University | Adaptive nanoparticle platforms for high throughput expansion and detection of antigen-specific t cells |
| US20240066062A1 (en) * | 2020-12-11 | 2024-02-29 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2022194742A1 (en) * | 2021-03-17 | 2022-09-22 | Miltenyi Biotec B.V. & Co. KG | Artificial target for the antigen-specific activation and expansion of car t cells |
| US20250032617A1 (en) * | 2021-10-08 | 2025-01-30 | Baylor College Of Medicine | Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers |
| WO2023144275A1 (en) * | 2022-01-28 | 2023-08-03 | Katholieke Universiteit Leuven | Actuation of organoids by magnetic nanoparticles |
| DE102022132082B4 (de) * | 2022-12-02 | 2024-08-08 | Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) | Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2311920C2 (ru) * | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| TW200502391A (en) * | 2003-05-08 | 2005-01-16 | Xcyte Therapies Inc | Generation and isolation of antigen-specific t cells |
| AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| CN102168066A (zh) * | 2011-01-31 | 2011-08-31 | 浙江大学 | 体外诱导乙型肝炎病毒特异性细胞毒性t淋巴细胞的方法 |
| JP6482461B2 (ja) * | 2012-07-13 | 2019-03-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 投与に関する形質導入ｔ細胞の適合性の評価方法 |
| KR102164405B1 (ko) * | 2013-03-14 | 2020-10-12 | 더 존스 홉킨스 유니버시티 | 나노스케일 인공 항원 제시 세포 |
| US11807675B2 (en) * | 2013-10-03 | 2023-11-07 | The University Of Maryland, Baltimore | Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells |
| US10066265B2 (en) * | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| KR20160016725A (ko) * | 2014-08-05 | 2016-02-15 | 주식회사 유영제약 | 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포 |
-
2017
- 2017-03-16 JP JP2018568171A patent/JP7016098B2/ja active Active
- 2017-03-16 WO PCT/US2017/022663 patent/WO2017161092A1/en not_active Ceased
- 2017-03-16 RU RU2021107053A patent/RU2021107053A/ru unknown
- 2017-03-16 CA CA3017615A patent/CA3017615A1/en active Pending
- 2017-03-16 EP EP17767506.3A patent/EP3445399A4/en active Pending
- 2017-03-16 CN CN201780030022.4A patent/CN109475620A/zh active Pending
- 2017-03-16 RU RU2018136203A patent/RU2745319C2/ru active
- 2017-03-16 KR KR1020187029819A patent/KR102470979B1/ko active Active
- 2017-03-16 SG SG10202008210XA patent/SG10202008210XA/en unknown
- 2017-03-16 AU AU2017233035A patent/AU2017233035B2/en active Active
- 2017-03-16 SG SG11201807940XA patent/SG11201807940XA/en unknown
- 2017-03-17 US US16/084,121 patent/US20200291381A1/en not_active Abandoned
-
2018
- 2018-09-12 IL IL261710A patent/IL261710A/en unknown
-
2023
- 2023-02-21 US US18/111,975 patent/US20230332131A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513412A5 (https=) | ||
| Huff et al. | The evolving role of CD8+ CD28− immunosenescent T cells in cancer immunology | |
| Parent et al. | Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection | |
| Pang et al. | Current progress of CAR-NK therapy in cancer treatment | |
| Lässer et al. | Isolation and characterization of RNA-containing exosomes | |
| JP6902018B2 (ja) | キメラ抗原受容体及び他の受容体の発現に対するｔ細胞 | |
| JP2016509839A5 (https=) | ||
| JP2016509840A5 (https=) | ||
| Suck et al. | Natural killer cells for therapy of leukemia | |
| Hefazi et al. | Regulatory T cell therapy of graft-versus-host disease: advances and challenges | |
| JP2016539929A5 (https=) | ||
| JP2013177430A5 (https=) | ||
| WO2018175408A8 (en) | METHODS AND COMPOSITIONS FOR MODULATION OF IMMUNE CELLS | |
| Stockinger et al. | CD4 T-cell memory | |
| Després et al. | CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device | |
| van Bruggen et al. | Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma | |
| Lee et al. | Phenotypic and functional changes of peripheral Ly6C+ T regulatory cells driven by conventional effector T cells | |
| Avecilla et al. | How do I perform hematopoietic progenitor cell selection? | |
| Fang et al. | Adoptive cell therapy for T-cell malignancies | |
| Gossel et al. | Retargeting of NK-92 cells against high-risk rhabdomyosarcomas by means of an ERBB2 (HER2/Neu)-specific chimeric antigen receptor | |
| Edri et al. | Nicotinamide-expanded allogeneic natural killer cells with CD38 deletion, expressing an enhanced CD38 chimeric antigen receptor, target multiple myeloma cells | |
| Plantinga et al. | Cord-blood-stem-cell-derived conventional dendritic cells specifically originate from CD115-expressing precursors | |
| Son et al. | Enhanced maturation and function of dendritic cells using hydrogel coated plate and antigen electroporation | |
| JP2020535832A5 (https=) | ||
| Kim et al. | X-ray as irradiation alternative for K562 feeder cell inactivation in human natural killer cell expansion |